First Bank & Trust Buys 80,401 Shares of Pfizer Inc. $PFE

First Bank & Trust increased its stake in Pfizer Inc. (NYSE:PFE) by 112.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,617 shares of the biopharmaceutical company’s stock after buying an additional 80,401 shares during the period. First Bank & Trust’s holdings in Pfizer were worth $3,863,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PFE. Financial Connections Group Inc. raised its position in shares of Pfizer by 573.3% in the 3rd quarter. Financial Connections Group Inc. now owns 8,221 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 7,000 shares in the last quarter. Spinnaker Investment Group LLC bought a new stake in shares of Pfizer during the third quarter valued at approximately $293,000. Charles Schwab Trust Co grew its stake in Pfizer by 51.4% in the third quarter. Charles Schwab Trust Co now owns 13,400 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 4,552 shares during the period. Thomasville National Bank raised its holdings in Pfizer by 0.8% in the third quarter. Thomasville National Bank now owns 88,231 shares of the biopharmaceutical company’s stock worth $2,248,000 after purchasing an additional 677 shares in the last quarter. Finally, Foster Victor Wealth Advisors LLC lifted its position in Pfizer by 9.4% during the third quarter. Foster Victor Wealth Advisors LLC now owns 705,258 shares of the biopharmaceutical company’s stock valued at $19,303,000 after buying an additional 60,667 shares during the period. 68.36% of the stock is owned by institutional investors.

Key Stores Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn’t Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Pfizer Trading Up 0.6%

Shares of NYSE PFE opened at $25.19 on Friday. The firm’s 50 day moving average price is $25.10 and its 200-day moving average price is $24.84. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market cap of $143.22 billion, a PE ratio of 14.65 and a beta of 0.46.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is currently 100.00%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.